Review of epidermal growth factor receptor-tyrosine kinase inhibitors administration to non-small-cell lung cancer patients undergoing hemodialysis

Figure 4 Pharmacokinetics of afatinib in patients undergoing hemodialysis and those with normal renal function. A: The C_max of afatinib 30 mg daily in patients with NRF was 16.3 ng/mL, while the C_max of afatinib 40 mg daily in patients with was NRF 25.2 ng/mL. The C_max of afatinib 30 mg daily in patients with HD was 13.4 ± 6.2 ng/mL on day 1 and 51.7 ± 23.8 ng/mL on day 10; B: The C_trough of afatinib 30 mg daily in patients with NRF was 15.1 ng/mL, while the C_trough of afatinib 40 mg daily in patients with NRF was 26 ng/mL. The C_trough of afatinib 30 mg daily in patients with HD was 4.5 ± 2.3 ng/mL on day 1 and 28.3 ± 9.0 ng/mL on day 11. C_max: Maxium concentration; C_trough: Trough concentration; HD: Hemodialysis; NRF: Normal renal function.